Bruton's酪氨酸激酶抑制剂Ibrutinib与B细胞肿瘤  

Bruton's tyrosine kinase inhibitor Ibrutinib and B-cell malignancy

作　　者：顾立超 王报春 陈乃耀[1] 

机构地区：[1]河北联合大学附属医院血液内科,河北唐山063000 [2]中国医学科学院血液学研究所贫血中心,天津300020

出　　处：《基础医学与临床》2014年第9期1281-1284,共4页Basic and Clinical Medicine

基　　金：河北省自然科学基金(H2013209253)

摘　　要：酪氨酸激酶的过度激活导致其下游信号途径的激活,最终导致细胞的转化、增殖和抵抗细胞凋亡,促进细胞生存。因此,许多学者致力于研究一些与肿瘤细胞分化增殖相关的细胞信号传导通路的关键酶作为药物筛选靶点,证实选择性作用于特定靶点的高效新型抗癌药物Bruton's酪氨酸激酶抑制剂Ibrutinib在初步抗B细胞肿瘤临床试验中具有非常好的疗效。Excessive activation of Burton＇s tyrosine kinase （BTK） resultes in transduction of downstream signaling pathways, which lead to transformation and proliferation of B cell tumors to resist apoptosis and promote cell survival. Therefore, many researchers have devoted to explore key BTK inhibitors against tumor cell proliferation-related cellular signal transduction pathway. Ibrutinib has been identified as a candidate drug with efficacy on specific target-BTK. So far, ibrutinib as a Bruton＇s tyrosine kinase inhibitor has become an important drug against B-cell tumor drugs and the patients with B-cell tumors showed quite good response to ibrutinib in the preliminary clinical trials.

关 键 词：Bruton's酪氨酸激酶 B细胞肿瘤 

分 类 号：R73-3[医药卫生—肿瘤]